title: Effect of aromatase inhibitors on bone mineral density in a Japanese breast cancer population.
abstract: We retrospectively analyzed the bone mineral density (BMD) of postmenopausal Japanese women taking an aromatase inhibitor (AI), exemestane, anastrozole or letrozole, and calculated the decrease rate constant of BMD in each individual to compare the influence of the three AIs on BMD. We also aimed to evaluate the preventive effect of bisphosphonates (BPs) on the AI-induced decrease in BMD. The decrease rate constant of BMD (k(e)) in each individual was determined as a slope of linear regression of the relationship between time and logarithm of BMD value in each patient during the AI therapy. To compensate for the age-related change in BMD level, we estimated the age-related decrease rate constant of BMD (ke,0) in healthy Japanese postmenopausal women from the literature. AIs decreased BMD with a ke value of -0.0329 yr(-1), which was 4.7-fold larger than the k(e,₀) value of -0.00699 yr(-1). No significant difference was detected in the influence on BMD among AIs. Co-administration of BP ameliorated the ke value to -0.0117 yr(-1), a value similar to k(e,₀). The influence of AIs on BMD was quantitatively evaluated by using the decrease rate constant of BMD (k(e)). The present study also suggests that BPs may be useful to prevent the decrease in BMD induced by AIs.
authors.affiliation: Department of Clinical Pharmacy, Keio University Faculty of Pharmacy.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Akiyoshi
authors.forename: Yuka
authors.initials: Y
authors.lastname: Shimomura
authors.forename: Shinichi
authors.initials: S
authors.lastname: Masuda
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Okamoto
authors.forename: Sumiko
authors.initials: S
authors.lastname: Hiura
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Kato
authors.forename: Toru
authors.initials: T
authors.lastname: Asayama
authors.forename: Hisakazu
authors.initials: H
authors.lastname: Ohtani
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000077384:Anastrozole; D000730:Androstadienes / Q000009:adverse effects; D047072:Aromatase Inhibitors / Q000009:adverse effects* / Q000494:pharmacology; D044466:Asian People; D015519:Bone Density / Q000187:drug effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004164:Diphosphonates / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000077289:Letrozole; D008875:Middle Aged; D009570:Nitriles / Q000009:adverse effects; D017698:Postmenopause; D012189:Retrospective Studies; D014230:Triazoles / Q000009:adverse effects
chemical_list: D000730:Androstadienes; D047072:Aromatase Inhibitors; D004164:Diphosphonates; D009570:Nitriles; D014230:Triazoles; D000077384:Anastrozole; D000077289:Letrozole; C056516:exemestane